Published in IJCP February 2023
Conference Proceedings
Diabetes India 2022: 12th World Congress of DiabetesIndia
February 11, 2023 | ijcp

Connected Blood Glucose Monitoring from Evidence to Clinical Practice

Dr Banshi Saboo, Ahmedabad

  • Blood glucose monitoring is a cornerstone for the management of diabetes and helps health care providers:
  • To assess glycemic control
  • Adjust therapy accordingly
  • Help patients modify their lifestyle accordingly.
  • Structured monitoring, pattern analysis and specific actions based on pattern providers better control of both hyperglycemia and hypoglycemia.
  • Patients and physicians connecting blood glucose monitors ease the burden such as logbook main­tenance, data sharing, evaluating blood glucose readings and remote monitoring.

PIONEERing the New Revolution in the Management of T2DM with Oral Semaglutide

Dr Anil Bhansali, Chandigarh

  • Oral semaglutide demonstrated significantly greater glycosylated hemoglobin (HbA1c) and weight reductions versus sitagliptin, empa­gliflozin and
  • Oral semaglutide is superior compared to empa­gliflozin and sitagliptin in controlling HbA1c, while noninferior to liraglutide.
  • Oral semaglutide has superior weight reduction properties compared to sitagliptin, linagliptin and empagliflozin.
  • Cardiovascular safety: Confirmed for oral sema­glutide in PIONEER 6, showing a 21% nonsignificant reduction in major adverse cardiovascular events in favor of oral semaglutide compared with placebo.
  • Overall safety: Oral semaglutide was well-tolerated with a safety profile consistent with the glucagon-like peptide-1 receptor agonist (GLP-1RA) class. The most common adverse event was mild to moderate nausea.
  • Efficacy was established when given early in therapy, late in therapy and regardless of renal or hepatic impairment.

2022 Update in Diabetes

Dr AK Das, Puducherry

  • Remarkable advances were observed in recent years in the management of patients with type 2 diabetes mellitus (T2DM) or type 1 diabetes mellitus (T1DM).
  • Regarding T2DM, changes in treatment paradigms were observed, moving from a glucocentric approach to a multi-risk strategy and, finally, in people at high-risk, to specific cardiorenal protection using new antidiabetic agents.
  • Regarding T1DM, progress combined new insulin analogs with better pharmacokinetics, continuous and flash glucose monitoring, and improved insulin delivery systems with smart insulin pens and insulin pumps connected to a glucose monitoring device, allowing better glucose control with less hypoglycemia.
  • Because of an increasing variety of therapeutic approaches, an individualized patient-centered strategy is recommended, ideally with the collabo­ration of a multidisciplinary team.
  • Artificial intelligence, digitization and telemedicine will play an increasing role in the management of T1DM and T2DM, in a near future.

Gliptin, Gliflozin, Synergy

Dr Vinod Mittal, New Delhi

  • Robust/rapid HbA1c reduction – no added hypoglycemia.
  • Weight loss – fat.
  • Decrease in SBP…Uric acid.
  • Cardiorenal protection.
  • Less GTI.
  • Cost, convenience, compliance.